PCDHB17P: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative diseases

Target Name: PCDHB17P

NCBI ID: G54661

PCDHB17P

Other Name(s): Protocadherin beta 17 pseudogene | PCDH-psi1 | PCDHB17 | ME4 | protocadherin beta 17 pseudogene

PCDHB17P: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative diseases

PCDHB17P is a protein that is expressed in various tissues and cells in the body. It is a part of the peroxisome proliferator-activated receptor (PPAR) family, which is a subset of the nuclear receptor family 7. PPARs are involved in the regulation of cellular processes that are related to inflammation, cell growth, and survival.

The discovery and characterization of PCDHB17P as a potential drug target and biomarker for inflammatory neurodegenerative diseases has gained significant attention in recent years. This protein has been shown to play a crucial role in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

PCDHB17P and its function

PCDHB17P is involved in the regulation of various cellular processes that are related to inflammation and neurodegeneration. It is a key regulator of the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6. These cytokines play a crucial role in the development and progression of neurodegenerative diseases.

In addition to its role in inflammation, PCDHB17P is also involved in the regulation of cellular processes that are related to cell survival and growth. It has been shown to play a role in the regulation of cell cycle progression, apoptosis, and autophagy.

PCDHB17P and its potential as a drug target

The potential use of PCDHB17P as a drug target is based on its involvement in the regulation of cellular processes that are related to inflammation and neurodegeneration. Several studies have shown that inhibiting the activity of PCDHB17P can protect against neurodegenerative diseases.

For example, several studies have shown that inhibiting the activity of PCDHB17P can protect against the development of neurodegenerative diseases, including Alzheimer's disease. In these studies, the use of PCDHB17P inhibitors has been shown to reduce the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6.

In addition to its potential as a neurodegenerative disease drug, PCDHB17P has also been shown to have potential as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. The use of PCDHB17P as a biomarker allows for the early detection and diagnosis of neurodegenerative diseases, which is crucial for proper treatment and management of these conditions.

PCDHB17P as a biomarker

PCDHB17P has been shown to play a role in the regulation of cellular processes that are related to neurodegeneration, including the production of pro-inflammatory cytokines and the regulation of cellular stress responses. This makes it an attractive candidate as a biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Studies have shown that the levels of PCDHB17P are significantly increased in the brains of individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This increased level of PCDHB17P is thought to contribute to the development and progression of these conditions.

In addition to its potential as a neurodegenerative disease biomarker, PCDHB17P has also been shown to have potential as a drug target. The use of PCDHB17P inhibitors has been shown to protect against the development of neurodegenerative diseases, including

Protein Name: Protocadherin Beta 17 Pseudogene

The "PCDHB17P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB17P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets